Science
The STACT™ platform is highly modular, allowing for the creation of multiple novel therapies that can be safely administered systemically, with capacity for multiple payloads. Through our precision engineering, the platform can be tuned to target and proliferate within diseased tissues beyond cancer.
The S. Typhimurium-Attenuated Cancer Therapy (STACT™) platform is highly modular, allowing for the creation of multiple novel therapies that can be safely administered systemically, with capacity to carry multiple payloads. Through our precision engineering, the platform is being used to create a portfolio of drug candidates that amplify and produce the payloads locally at the disease site, thereby avoiding therapeutic limiting systemic toxicity experienced when the payloads are administered by other means.
The Problem
The majority of solid tumors do not respond to current immuno-oncology drugs. Tragically, patients with these tumors are left without options, as tumor resistance makes harnessing the full potential of the anti-tumor immune response incredibly challenging.
The broad immune response needed to circumvent tumor resistance is difficult to generate in the tumor without creating a systemic immune response that can be harmful to the patient. To systemically deliver a drug that activates a durable immune response at the site of the tumor remains a major challenge.
The majority of solid tumors do not respond to current immuno-oncology drugs. Tragically, patients with these tumors are left without options, as tumor resistance makes harnessing the full potential of the anti-tumor immune response incredibly challenging.
The broad immune response needed to circumvent tumor resistance is difficult to generate in the tumor without creating a systemic immune response that can be harmful to the patient. To systemically deliver a drug that activates a durable immune response at the site of the tumor remains a major challenge.
The Problem
The unique engineering of the STACT™ platform for systemic delivery enables preferential localization and proliferation of the bacteria within the tumor. Uptake by resident myeloid immune cells – critically involved in the regulation of tumor growth and metastasis – initiates activation of the innate immune system, and with the right choice of payload, we maximally engage innate immunity and activate and support the adaptive immune system to create a strong, durable anti-tumor immune response.
The unique engineering of the STACT™ platform for systemic delivery enables preferential localization and proliferation of the bacteria within the tumor. Uptake by resident myeloid immune cells – critically involved in the regulation of tumor growth and metastasis – serves to activate the innate immune system, and with the right choice of payload, we activate the adaptive immune system to create a strong, durable anti-tumor immune response.
The Solution
